ImmuneWatch
ActiveImmuneWatch has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-30k) and a net result of €9k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 10% of 524 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
Checked score
Score 2025
57
/ 100
Fair
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability75▲+25
Solvency8▼-4
Growth58=
Track record94
Bankruptcy probability, 12 months
1.1%
Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity ample (current ratio 2.44 against 6.59 in 2024; short-term debt: 35.2% and cash: 34% of total assets), but equity is negative.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-17.4%
Return on assets
4.9%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 10% of 524 sector peers (2025).
NBB · sector comparisonPosition among 524 sector peers
Solvency
better than 10%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 20-07-2026, 11 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
11 d early
2024
20 d early
2023
43 d early
2022
40 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
23-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€-30k▲ 22.0%
2024 · €-39k
2022: €110k
2023: €42k
2024: €-39k
2022 → 2025
Total assets
€174k▼ 42.0%
2024 · €300k
2022: €196k
2023: €395k
2024: €300k
2022 → 2025
Net result
€9k
2024 · €-81k
2022: €-122k
2023: €-68k
2024: €-81k
2022 → 2025
Working capital
€88k▼ 63.6%
2024 · €242k
2022: €165k
2023: €355k
2024: €242k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€110k-€42k▼ 61.9%€-39k€-30k▲ 22.0%
Operating result€-121k-€-82k▲ 32.2%€-83k▼ 1.0%€4k
Net result€-122k-€-68k▲ 44.2%€-81k▼ 18.6%€9k
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result returns to profit in 2025: €4k after a loss of €83k in 2024, the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €174k
Fixed assets
€24k▲ 73.2%
Current assets
€149k▼ 47.7%
Key figures and ratios
EBITDA
€216k▲
2024 · €59k
Cash flow
€220k▲
2024 · €61k
Solvency
-17.4%▼
2024 · -12.9%
Current ratio
2.44▼
2024 · 6.59
Quick ratio
2.44▼
2024 · 6.59
Debt / equity
-6.75▲
2024 · -8.74
ROA
4.9%▲
2024 · -26.9%
Interest coverage
38.15▲
2024 · 27.48
Debt
€204k▼
2024 · €339k
Debt ≤ 1 year
€61k▲
2024 · €43k
Debt > 1 year
€0▼
2024 · €15k
Income taxes
€-8k▼
2024 · €-4k
Staff costs
€56k▲
2024 · €51k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€300k€174k▼
Fixed assets21/28€14k€24k▲
Intangible fixed assets21€12k€23k▲
Tangible fixed assets22/27€2k€1k▼
Furniture and vehicles24€2k€1k▼
Current assets29/58€286k€149k▼
Amounts receivable after more than one year29€19k€28k▲
Other amounts receivable291€19k€28k▲
Amounts receivable within one year40/41€32k€53k▲
Trade receivables40€21k€15k▼
Other amounts receivable41€11k€39k▲
Cash at bank and in hand54/58€222k€59k▼
Deferred charges and accrued income490/1€12k€9k▼
Equity and liabilities
Total equity and liabilities10/49€300k€174k▼
Equity10/15€-39k€-30k▲
Contributions10/11€232k€232k=
Profit (loss) carried forward14€-270k€-262k▲
Amounts payable17/49€339k€204k▼
Amounts payable after more than one year17€15k€0▼
Financial debts170/4€15k€0▼
Amounts payable within one year42/48€43k€61k▲
Current portion of amounts payable after more than one year42-€15k
Trade debts44€36k€38k▲
Suppliers440/4€36k€38k▲
Taxes, remuneration and social security45€7k€8k▲
Remuneration and social security454/9€7k€8k▲
Other amounts payable47/48€58€255▲
Accrued charges and deferred income492/3€280k€143k▼
Income statement
Code20242025
Remuneration, social security and pensions62€51k€56k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€142k€211k▲
Other operating charges640/8€580€595▲
Gross operating margin9900€110k€272k▲
Operating profit (loss)9901€-83k€4k▲
Financial income75/76B€0€2k▲
Recurring financial income75€0€2k▲
Financial charges65/66B€2k€6k▲
Recurring financial charges65€2k€6k▲
Profit (loss) for the period before taxes9903€-85k€454▲
Income taxes67/77€-4k€-8k▼
Profit (loss) for the period9904€-81k€9k▲
Profit (loss) for the period to be appropriated9905€-81k€9k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-270k€-262k▲
Profit (loss) brought forward from the previous period14P€-190k€-270k▼
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
20-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Back to profitnet €9k
Net result €9k after 3 loss-making years.
11-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
18-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
21-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
5 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Antwerpen · 1 establishment unit since 2021
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Lange Gasthuisstraat 29-312000 AntwerpenGround area
2,666 m²
Building footprint
484 m²
Volume, LiDAR
6,880 m³
Parcel 11803C0969/00B000, Flanders · tallest building 18.0 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
Lange Gasthuisstraat 29-31, 2000 Antwerpen
since 20212.321.906.420
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11803C0969/00B000 | Flanders | 2,666 m² | 1 · 483 m² | 18.0 m · 5 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).
Public money · subsidies and aid
Flemish government
2022 to 2025 · 5 entries · 146,541 EUR awarded · 146,541 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 1 | 4,080 EUR | 4,080 EUR |
| 2024 | 3 | 10,764 EUR | 38,461 EUR |
| 2022 | 1 | 131,697 EUR | 104,000 EUR |
Schemes
Ontwikkelingsproject
Subsidies voor internationaal ondernemen
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
European Union, budget
2023 to 2025 · 6 entries · 1,037,709 EUR in total| Year | Entries | awarded |
|---|---|---|
| 2025 | 2 | 62,811 EUR |
| 2023 | 4 | 974,898 EUR |
Projects
101081028 - CAPTIVATE - CORRELATES OF PROTECTIVE IMMUNITY-DRIVEN INVESTIGATION OF MALARIA VACCINE COMBINATION STRATEGIES
101081028 - CAPTIVATE - CORRELATES OF PROTECTIVE IMMUNITY-DRIVEN INVESTIGATION OF MALARIA VACCINE COMBINATION STRATEGIES
101137459 - YELLOW4FLAVI - DECONSTRUCTING THE PROTECTIVE IMMUNITY OF YELLOW FEVER VIRUS 17D TO INFORM FLAVIVIRUS VACCINE DESIGN
101137459 - YELLOW4FLAVI - DECONSTRUCTING THE PROTECTIVE IMMUNITY OF YELLOW FEVER VIRUS 17D TO INFORM FLAVIVIRUS VACCINE DESIGN
CORRELATES OF PROTECTIVE IMMUNITY-DRIVEN INVESTIGATION OF MALARIA VACCINE COMBINATION STRATEGIES
Show 1 more projects
DECONSTRUCTING THE PROTECTIVE IMMUNITY OF YELLOW FEVER VIRUS 17D TO INFORM FLAVIVIRUS VACCINE DESIGN
European research
3 projects · 974,896 EUR EU contributionProgrammes
HORIZON
Projects
CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combinaTion stratEgies
Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design
Developing Immune Strategies to Counter tumor-immune-micrOnVironmEntal Resistance in NeuroEndocrine Tumors.
Similar companies · same sector, comparable size
BIOGRABBIT
BE 1009.728.131
Dendermonde · Eq €42k
Elegent
BE 0784.411.383
Gent · Eq €42k
Dokter Sara Van Soom, huisarts
BE 0632.552.143
Edegem · Eq €43k
EUROPHARMEDTECH
BE 0685.431.593
Ganshoren · Eq €41k
IPM IMPACT
BE 0825.883.734
Hasselt · Eq €43k
Of 761 companies in sector 72101 we hold annual accounts for 481. 227 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded23-09-2021
Fiscal year end31-12
Activities, NACEBEL
72101Research and development on biotechnology
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Data from official sources, last processed on 23-09-2026. Scores and ratios are computed by Checked and are not a credit decision.